Dyadic International Inc. (NASDAQ:DYAI) Short Interest Down 26.4% in January
by Scott Moore · The Cerbat GemDyadic International Inc. (NASDAQ:DYAI – Get Free Report) was the target of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totaling 147,183 shares, a decrease of 26.4% from the December 31st total of 200,065 shares. Based on an average daily volume of 48,097 shares, the days-to-cover ratio is presently 3.1 days. Approximately 0.6% of the shares of the stock are sold short. Approximately 0.6% of the shares of the stock are sold short. Based on an average daily volume of 48,097 shares, the days-to-cover ratio is presently 3.1 days.
Analyst Ratings Changes
Several brokerages have recently commented on DYAI. HC Wainwright began coverage on shares of Dyadic International in a research report on Thursday, October 23rd. They issued a “buy” rating and a $3.00 target price for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a research report on Monday, December 29th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $3.00.
View Our Latest Stock Analysis on Dyadic International
Dyadic International Trading Down 3.8%
NASDAQ:DYAI traded down $0.03 during mid-day trading on Friday, hitting $0.87. 40,013 shares of the company’s stock were exchanged, compared to its average volume of 30,533. Dyadic International has a fifty-two week low of $0.71 and a fifty-two week high of $1.73. The company has a current ratio of 2.85, a quick ratio of 2.85 and a debt-to-equity ratio of 1.92. The firm has a market capitalization of $31.52 million, a P/E ratio of -3.63 and a beta of 1.26. The company has a 50 day simple moving average of $0.93 and a 200-day simple moving average of $0.98.
Dyadic International (NASDAQ:DYAI – Get Free Report) last released its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.02). Dyadic International had a negative net margin of 221.09% and a negative return on equity of 537.31%. The business had revenue of $1.16 million for the quarter, compared to the consensus estimate of $1.22 million. As a group, research analysts expect that Dyadic International will post -0.18 earnings per share for the current year.
Institutional Investors Weigh In On Dyadic International
Institutional investors and hedge funds have recently made changes to their positions in the stock. Marathon Capital Management lifted its stake in shares of Dyadic International by 142.9% in the fourth quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 50,000 shares during the period. Landscape Capital Management L.L.C. bought a new position in Dyadic International during the 3rd quarter worth approximately $190,000. Bank of America Corp DE raised its holdings in Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 26,965 shares during the last quarter. Apis Capital Advisors LLC bought a new stake in shares of Dyadic International in the 3rd quarter valued at $1,817,000. Finally, Truist Financial Corp boosted its stake in shares of Dyadic International by 30.5% in the 3rd quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock valued at $385,000 after purchasing an additional 76,200 shares during the last quarter. Institutional investors and hedge funds own 27.95% of the company’s stock.
About Dyadic International
Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.
The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.